Jaiswal Mamta, Tripathi Archana, Singh Dezy, Kumar Arvind, Singh Monika, Batra Neha, Verma Anil
Pathology, Guru Shri Gorakhnath Chikitsalaya, Gorakhpur, IND.
Pathology, Baba Raghav Das Medical College, Gorakhpur, IND.
Cureus. 2022 Feb 17;14(2):e22346. doi: 10.7759/cureus.22346. eCollection 2022 Feb.
Background/Aims Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor. Cyclin D1 is a protein that in humans is encoded by the CCND1 gene. Cyclin D1 protein is frequently overexpressed in malignant gliomas. Methods It is an observational study comprising 40 biopsy-proven cases of GBM in a span of one and half years. Immunohistochemistry (IHC) was used with Cyclin D1 monoclonal antibody. Cyclin D1 on the outcome was assessed using the Kaplan-Meier survival estimate and compared by log-rank test. Results Cyclin D1 was expressed in 60% of patients. The majority (72.5%) of patients expired during the study period, out of which 69% showed immune-expression in contrast to living subjects, out of which only 45.5% of patients exhibited expression. The maximum number of glioblastoma patients were aged between 41 and 50 years (40%), followed by those aged between 31 and 40 years (20%). The male to female ratio of study subjects was 3.44:1. Conclusion The study concluded that there is no significant association between Cyclin D1 expression status and different demographic, clinical, and outcome variables.
背景/目的 多形性胶质母细胞瘤（GBM）是最具侵袭性的原发性脑肿瘤。细胞周期蛋白D1是一种在人类中由CCND1基因编码的蛋白质。细胞周期蛋白D1蛋白在恶性胶质瘤中经常过度表达。方法 这是一项观察性研究，在一年半的时间里纳入了40例经活检证实的GBM病例。使用细胞周期蛋白D1单克隆抗体进行免疫组织化学（IHC）检测。使用Kaplan-Meier生存估计评估细胞周期蛋白D1对预后的影响，并通过对数秩检验进行比较。结果 60%的患者表达细胞周期蛋白D1。在研究期间，大多数（72.5%）患者死亡，其中69%的死亡患者显示免疫表达，而存活患者中只有45.5%的患者表达。胶质母细胞瘤患者数量最多的年龄段为41至50岁（40%），其次是31至40岁（20%）。研究对象的男女比例为3.44:1。结论 该研究得出结论，细胞周期蛋白D1表达状态与不同的人口统计学、临床和预后变量之间没有显著关联。
